Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Ezetimib bei Hypercholesterinämie. [Ezetimibe for hypercholesterolaemia] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 90. 2011 Authors' objectives In its letter of 20 May 2010, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess ezetimibe (in mono- or combination therapy) in patients with hypercholesterolaemia. Authors' conclusions In patients with hypercholesterolaemia there is no proof of a benefit or harm from ezetimibe therapy compared with placebo. This applies both to monotherapy and combination therapy. No studies on monotherapy were available. Likewise, there is no proof of an additional or lesser benefit, or for greater or lesser harm from ezetimibe compared with other lipid-lowering agents or with non-drug treatment interventions. This applies both to monotherapy and combination therapy. No studies on monotherapy were available. Indexing Status Subject indexing assigned by CRD MeSH Anticholesteremic Agents; Azetidines; Hypercholesterolemias Language Published English Country of organisation Germany English summary An English language summary is available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32012000294 Date abstract record published 13/07/2012 |